ERBB2 and breast carcinoma: In vitro experiments demonstrated selective targeting of the 4-component “antibody-C11Pc-PEGAuNPs” conjugates to breast cancer cells overexpressing the HER2 epithelial cell growth factor receptor, and efficacy in PDT applications, but no in vivo results were presented [84].